FRA
UTHR icon

Frank Rimerman Advisors’s United Therapeutics UTHR Stock Holding History

Frank Rimerman Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Sell
383
-5
-1% -$2.82K 0.01% 594
2026
Q1 		$230K Buy
+388
New +$193K 0.02% 549

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Frank Rimerman Advisors's UTHR Position: Q2 2026 in Review

Frank Rimerman Advisors reduced its United Therapeutics (UTHR) stake by 1.3% in Q2 2026, selling an estimated $2.82K and leaving 383 shares worth $208K. The position accounts for 0.01% of the portfolio, ranked #594.

Frank Rimerman Advisors first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $230K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Frank Rimerman Advisors held 383 shares of United Therapeutics worth $208K as of Q2 2026.
  • Frank Rimerman Advisors sold 5 United Therapeutics shares in Q2 2026, an estimated $2.82K.
  • United Therapeutics made up 0.01% of Frank Rimerman Advisors's portfolio in Q2 2026, its #594 holding.
  • Frank Rimerman Advisors first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Frank Rimerman Advisors's United Therapeutics position peaked at $230K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.